

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2025 P 2316-3
Program	Prior Authorization/Medical Necessity
Medication	Xdemvy™ (lotilaner) ophthalmic solution 0.25%
P&T Approval Date	11/2023, 11/2024, 11/2025 11/2025
Effective Date	2/15/2026

1. Background:

Xdemvy (lotilaner) ophthalmic solution 0.25% is indicated for the treatment of Demodex blepharitis.

2. Coverage Criteria^a:

A. Authorization

1. **Xdemvy** will be approved based on **all** of the following criteria:

a. Diagnosis of *Demodex* blepharitis

-AND-

b. Patient demonstrates **one** of the following signs of *Demodex* infestation

- 1) Cylindrical cuff at the root of the eyelashes
- 2) Lid margin erythema
- 3) Eyelash anomalies (eyelash misdirection)

-AND-

c. Patient demonstrates **two** of the following symptoms of *Demodex* infestation

- 1) Itching/Burning
- 2) Foreign body sensation
- 3) Crusting/matter lashes
- 4) Blurry vision
- 5) Discomfort/irritation

-AND-

d. Patient is practicing good eye-lid hygiene (e.g., non-prescription tree-tea oil)

-AND-

e. Prescribed by or in consultation with **one** of the following:

- 1) Ophthalmologist
- 2) Optometrist

Authorization will be issued for 3 months

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Xdemvy [package insert]. Irvine, CA: Tarsus Pharmaceuticals, Inc. July 2023.
2. M.T Yen. Demodex Infestation. American Academy of Ophthalmology. EyeWiki. April 2025.

Program	Prior Authorization/Medical Necessity – Xdemvy
Change Control	
Date	Change
11/2023	New program
11/2024	Annual review. No changes
11/2025	Annual review. Updated references.